- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00293033
Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
A Double-blind, Placebo Controlled Evaluation of the Efficacy, Safety and Tolerability of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskelupaikat
-
-
North Carolina
-
Wilmington, North Carolina, Yhdysvallat, 28412
- PPD Development
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Male or non-pregnant and non-lactating female. A female of child-bearing potential is eligible to participate in this study if she is using an acceptable method of birth control.
- 18 years or older
- Patient must have pain associated with cancer or cancer treatment.
- Patient must be on a stable current regimen of oral opioids equivalent to 60 - 1000 mg/day of oral morphine or 50 - 300 µg/hr of transdermal fentanyl (e.g. oxycodone 30 mg, methadone 20 mg, and hydromorphone 7.5 mg).
- Regularly experiences 1 - 4 breakthrough pain episodes per day that require additional opioids for pain control
- At least partial relief of breakthrough pain by use of opioid therapy
- Subject must be able to self-administer the study medication correctly.
- Subject must be willing and able to complete the electronic diary card with each pain episode.
- Signed consent must be obtained at screening prior to any procedures being performed.
Exclusion Criteria:
- Psychiatric/cognitive or neurological impairment that would limit the subject's ability to understand or complete the diary
- Cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of respiratory depression
- Recent history or current evidence of alcohol or other drug substance (licit or illicit) abuse
- Rapidly escalating pain that the investigator believes may require an increase in the dosage of background pain medication during the study
- Moderate (Grade 3) to severe (Grade 4) mucositis (Subjects with less than moderate mucositis are permitted and must be instructed to not apply the BEMA disc at a site of inflammation.)
- Strontium 89 therapy within the previous 6 months
- Any other therapy prior to the study that the investigator considers could alter pain or the response to pain medication.
- Use of an investigational drug within 4 weeks preceding this study
- History of hypersensitivity or intolerance to fentanyl
- Regularly more than 4 episodes per day
- Eastern Cooperative Oncology Group (ECOG) performance status of 4 or 5
- Subject is pregnant, actively trying to become pregnant, breast feeding or not using adequate contraceptive measures
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Placebo Comparator: Plasebo
|
BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form.
The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth.
The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened.
The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
Muut nimet:
|
Kokeellinen: BEMA™ Fentanyl
BioErodible MucoAdhesive (BEMA) Fentanyl
|
BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form.
The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth.
The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened.
The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Summary of Pain Intensity Differences (SPID)
Aikaikkuna: 0-30 minutes
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. |
0-30 minutes
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
SPID
Aikaikkuna: 0-5 minutes
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study.
SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes).
Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
|
0-5 minutes
|
SPID
Aikaikkuna: 0-10 minutes
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study.
SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes).
Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
|
0-10 minutes
|
SPID
Aikaikkuna: 0-15 minutes
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study.
SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes).
Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
|
0-15 minutes
|
SPID
Aikaikkuna: 0-45 minutes
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study.
SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes).
Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
|
0-45 minutes
|
SPID
Aikaikkuna: 0-60 minutes
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study.
SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes).
Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
|
0-60 minutes
|
PID
Aikaikkuna: 5 minutes after dosing
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
|
5 minutes after dosing
|
PID
Aikaikkuna: 10 minutes after dosing
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
|
10 minutes after dosing
|
PID
Aikaikkuna: 15 minutes after dosing
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
|
15 minutes after dosing
|
PID
Aikaikkuna: 30 minutes after dosing
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
|
30 minutes after dosing
|
PID
Aikaikkuna: 45 minutes after dosing
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
|
45 minutes after dosing
|
PID
Aikaikkuna: 60 minutes after dosing
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
|
60 minutes after dosing
|
Pain Relief
Aikaikkuna: 5 minutes after dosing
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
|
5 minutes after dosing
|
Pain Relief
Aikaikkuna: 10 minutes after dosing
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
|
10 minutes after dosing
|
Pain Relief
Aikaikkuna: 15 minutes after dosing
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
|
15 minutes after dosing
|
Pain Relief
Aikaikkuna: 30 minutes after dosing
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
|
30 minutes after dosing
|
Pain Relief
Aikaikkuna: 45 minutes after dosing
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
|
45 minutes after dosing
|
Pain Relief
Aikaikkuna: 60 minutes after dosing
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
|
60 minutes after dosing
|
Total Pain Relief
Aikaikkuna: 5 minutes
|
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest.Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
|
5 minutes
|
Total Pain Relief
Aikaikkuna: 10 minutes
|
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest.
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
|
10 minutes
|
Total Pain Relief
Aikaikkuna: 15 minutes
|
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest.
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
|
15 minutes
|
Total Pain Relief
Aikaikkuna: 30 minutes
|
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest.
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
|
30 minutes
|
Total Pain Relief
Aikaikkuna: 45 minutes
|
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest.
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
|
45 minutes
|
Total Pain Relief
Aikaikkuna: 60 minutes
|
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest.
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
|
60 minutes
|
Subject Overall Satisfaction With Study Drug
Aikaikkuna: 60 minutes or at time of rescue medication use
|
Subjects evaluated their overall satisfaction with study drug at the time rescue medication was consumed or at the 60-minute time point using a 5-point categorical scale (0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent).
|
60 minutes or at time of rescue medication use
|
Percentage of Pain Free Episodes
Aikaikkuna: 5 minutes
|
A pain free episode is one with 0 pain intensity at the specified time point.
Percentage of episodes that are pain-free per subject is analyzed.
|
5 minutes
|
Percentage of Pain Free Episodes
Aikaikkuna: 10 minutes
|
A pain free episode is one with 0 pain intensity at the specified time point.
Percentage of episodes that are pain-free per subject is analyzed.
|
10 minutes
|
Percentage of Pain Free Episodes
Aikaikkuna: 15 minutes
|
A pain free episode is one with 0 pain intensity at the specified time point.
Percentage of episodes that are pain-free per subject is analyzed.
|
15 minutes
|
Percentage of Pain Free Episodes
Aikaikkuna: 30 minutes
|
A pain free episode is one with 0 pain intensity at the specified time point.
Percentage of episodes that are pain-free per subject is analyzed.
|
30 minutes
|
Percentage of Pain Free Episodes
Aikaikkuna: 45 minutes
|
A pain free episode is one with 0 pain intensity at the specified time point.
Percentage of episodes that are pain-free per subject is analyzed.
|
45 minutes
|
Percentage of Pain Free Episodes
Aikaikkuna: 60 minutes
|
A pain free episode is one with 0 pain intensity at the specified time point.
Percentage of episodes that are pain-free per subject is analyzed.
|
60 minutes
|
Episodes With at Least 50% Decreases in Pain
Aikaikkuna: 15 minutes
|
Number of episodes where the total pain score has at least a 50% reduction from baseline.
|
15 minutes
|
Episodes With at Least 50% Decreases in Pain
Aikaikkuna: 30 minutes
|
Number of episodes where the total pain score has at least a 50% reduction from baseline.
|
30 minutes
|
Episodes With at Least 50% Decreases in Pain
Aikaikkuna: 45 minutes
|
Number of episodes where the total pain score has at least a 50% reduction from baseline.
|
45 minutes
|
Episodes With at Least 50% Decreases in Pain
Aikaikkuna: 60 minutes
|
Number of episodes where the total pain score has at least a 50% reduction from baseline.
|
60 minutes
|
Episodes With at Least 33% Decreases in Pain
Aikaikkuna: 15 minutes
|
Number of episodes where the total pain score has at least a 33% reduction from baseline.
|
15 minutes
|
Episodes With at Least 33% Decreases in Pain
Aikaikkuna: 30 minutes
|
Number of episodes where the total pain score has at least a 33% reduction from baseline.
|
30 minutes
|
Episodes With at Least 33% Decreases in Pain
Aikaikkuna: 45 minutes
|
Number of episodes where the total pain score has at least a 33% reduction from baseline.
|
45 minutes
|
Episodes With at Least 33% Decreases in Pain
Aikaikkuna: 60 minutes
|
Number of episodes where the total pain score has at least a 50% reduction from baseline.
|
60 minutes
|
Episodes With Complete Pain Relief
Aikaikkuna: 5 minutes
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).
Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
|
5 minutes
|
Episodes With Complete Pain Relief
Aikaikkuna: 10 minutes
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
|
10 minutes
|
Episodes With Complete Pain Relief
Aikaikkuna: 15 minutes
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
|
15 minutes
|
Episodes With Complete Pain Relief
Aikaikkuna: 30 minutes
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).
Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
|
30 minutes
|
Episodes With Complete Pain Relief
Aikaikkuna: 45 minutes
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).
Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
|
45 minutes
|
Episodes With Complete Pain Relief
Aikaikkuna: 60 minutes
|
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).
Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
|
60 minutes
|
Rescue Medication Usage
Aikaikkuna: 28 Days
|
Rescue medication is medication taken if adequate pain relief is not realized within 30 minutes following application of the study drug.
Percentage of episodes when rescue medication was used per subject is analyzed.
|
28 Days
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
SPID in Neuropathic Pain Subpopulation
Aikaikkuna: 15 minutes
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study.
SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes).
Higher value indicates a better outcome.
SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes).
Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
|
15 minutes
|
SPID in Neuropathic Pain Subpopulation
Aikaikkuna: 30 minutes
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study.
SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes).
Higher value indicates a better outcome.
SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes).
Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
|
30 minutes
|
SPID in Neuropathic Pain Subpopulation
Aikaikkuna: 45 minutes
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study.
SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes).
Higher value indicates a better outcome.
SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes).
Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
|
45 minutes
|
SPID in Neuropathic Pain Subpopulation
Aikaikkuna: 60 minutes
|
Pain intensity (using an 11-point [0 = no pain to 10 = worst pain] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing.
Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study.
SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes).
Higher value indicates a better outcome.
SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes).
Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
|
60 minutes
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojen puheenjohtaja: Andrew Finn, PharmD, BioDelivery Sciences International
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Kipu
- Neurologiset ilmenemismuodot
- Läpimurtokipu
- Huumeiden fysiologiset vaikutukset
- Keskushermostoa lamaavat aineet
- Ääreishermoston aineet
- Analgeetit
- Aistijärjestelmän agentit
- Anestesia-aineet, suonensisäiset
- Anestesia, kenraali
- Anestesia-aineet
- Analgeetit, opioidit
- Huumausaineet
- Adjuvantit, anestesia
- Fentanyyli
Muut tutkimustunnusnumerot
- FEN-201
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Kipu
-
Alanya Alaaddin Keykubat UniversityValmisSterilointi, tubal | Visual Analog Pain Scale
-
Korea University Anam HospitalKorea UniversityValmisKivun mittaus | Visual Analog Pain Scale
-
Turkish Ministry of Health, Kahramanmaras Provincial...Rekrytointi
-
Fujian Cancer HospitalEi vielä rekrytointiaHawthorn Red Combined Refractory Cancer Pain
-
Sobet AGLa Tour Hospital; Klinikum Klagenfurt am Wörthersee; Krankenhaus der Elisabethinen... ja muut yhteistyökumppanitRekrytointiMyofascial Pain Syndrome - Alaselkä | Myofascial Pain Syndrome - Niska | Myofascial Pain Syndrome - jännityspäänsärkyItävalta, Sveitsi
-
Ankara UniversityValmisKivun mittaus | Visual Analogue Pain ScaleTurkki
-
Yuzuncu Yıl UniversityValmisMyofascial Pain Disfunction -oireyhtymä, temporomandibulaarinen nivelTurkki
-
East Carolina UniversityPeruutettu
-
Washington University School of MedicinePeruutettuBruksismi | Temporomandibulaariset nivelsairaudet | Temporomandibulaarinen nivelen toimintahäiriö | Myofascial Pain Disfunction -oireyhtymä, temporomandibulaarinen nivelYhdysvallat
-
Quiropraxia y EquilibrioUniversidad Nacional Andres BelloValmisMyofascial Trigger Point Pain (MTrP)Chile
Kliiniset tutkimukset Plasebo
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyValmisMiespotilaat, joilla on tyypin II diabetes (T2DM)Saksa
-
National Institute on Drug Abuse (NIDA)ValmisKannabiksen käyttöYhdysvallat
-
Chiesi Farmaceutici S.p.A.ValmisAstmaYhdistynyt kuningaskunta
-
Eli Lilly and CompanyLopetettuNivelreumaYhdysvallat, Saksa, Taiwan, Ranska, Japani, Meksiko, Puola, Venäjän federaatio, Espanja, Kolumbia, Argentiina, Kreikka, Uusi Seelanti, Etelä-Afrikka, Australia, Korean tasavalta, Brasilia, Italia, Malesia
-
MedImmune LLCValmis
-
Alzheon Inc.National Institute on Aging (NIA)Aktiivinen, ei rekrytointiVarhainen Alzheimerin tautiYhdysvallat, Espanja, Kanada, Alankomaat, Tšekki, Yhdistynyt kuningaskunta, Ranska, Saksa, Islanti
-
GlaxoSmithKlineValmisLihavuus | Diabetes mellitus, tyyppi 2Yhdistynyt kuningaskunta
-
Vitae Pharmaceuticals Inc., an Allergan affiliateValmis
-
Starpharma Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... ja muut yhteistyökumppanitValmisTerveYhdysvallat, Puerto Rico
-
CONRADRTI International; Match Research; UZ-UCSF Collaborative Research ProgrammeValmisHIV | EhkäisyEtelä-Afrikka, Zimbabwe